# Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib

> **NCT00667147** · PHASE1 · COMPLETED · sponsor: **University of Southern California** · enrollment: 65 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Weekly Abraxane and Daily Vandetanib
- **DRUG:** Abraxane every three weeks and daily vandetanib

## Key facts

- **NCT ID:** NCT00667147
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-05
- **Final completion:** 2014-06
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2014-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667147, "Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00667147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*